Plural Hetero Atoms In The Tricyclo Ring System Patents (Class 514/291)
  • Patent number: 11351120
    Abstract: The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: June 7, 2022
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Stephen D. Collins, Peter J. Goldstein, Joshua T. Johnstone
  • Patent number: 11343914
    Abstract: An electronic device is provided. The electronic device includes a conductive support member, a first circuit board connected to the conductive support member by a first capacitor, a second circuit board connected to the conductive support member by a second capacitor, a first conductive connection member electrically connecting the first circuit board and the second circuit board, and a first ground structure, at least a portion of the first ground structure being interposed between the first conductive connection member and the conductive support member. The ground structure includes a non-conductive layer physically contacting the conductive support member, and a conductive layer electrically connected to the first conductive connection member to form a capacitive coupling with the conductive support member.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: May 24, 2022
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Wangik Son, Minho Kim, Sunghyun Kim, Eungwon Kim, Chanbeom Jeong
  • Patent number: 11285116
    Abstract: Recently, we have introduced fibrous dosage forms that enable predictable microstructures with a greater range of pharmaceutically relevant properties. Presented herein, accordingly, is a method for the manufacture of such fibrous dosage forms. The method includes extruding a plasticized matrix through an exit port of an extrusion channel to form one or more plasticized fibers, structuring said fibers to a three dimensional structural network by patterning on a translating or rotating stage, and solidifying the patterned structure.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: March 29, 2022
    Inventor: Aron H. Blaesi
  • Patent number: 11285081
    Abstract: In order to enable long-term stabilization of rapamycin contained in a liquid formulation, a formulation sealing vessel of the present invention includes: a sealed vessel body in which a liquid formulation containing 2% (w/w) rapamycin or a salt thereof, 94% (w/w) polyethylene glycol, and 4% (w/w) ethanol is sealed, the sealed vessel body having a volume of 0.1 mL to 1.0 mL, the liquid formulation containing no antioxidant, and the liquid formulation having a total volume of 0.02 mL to 1.0 mL.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: March 29, 2022
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Sreenivasu Mudumba, Kedar Datar, Hiromitsu Shiono, Chun-jung Chu, Le An, Sudeep Rauser
  • Patent number: 11208475
    Abstract: The present invention provides methods for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators, such as serotonin receptor activating antibodies, among others. The invention also features compositions containing serotonin receptor activators, methods of diagnosing patients with a serotonin receptor-associated inflammatory or autoimmune disease or condition, and methods of predicting the response of an inflammatory or autoimmune disease or condition in a subject to treatment with serotonin receptor activators.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: December 28, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, George Huck Neubauer, Manuel Andreas Fankhauser, Julian Alexander Stanley
  • Patent number: 11179374
    Abstract: The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: November 23, 2021
    Assignee: Drexel University
    Inventors: Christian Sell, Timothy Nacarelli, Ashley Azar
  • Patent number: 11103449
    Abstract: The present invention relates to methods and compositions for anti-aging therapy and for the treatment and prophylaxis of age-related diseases and disorders in a human subject in need of such therapy or treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation, of composition comprising rapamycin, or a prodrug or derivative thereof.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: August 31, 2021
    Assignee: AI Therapeutics, Inc.
    Inventors: Thomas Armer, Lawrence S. Melvin, Jr., Jonathan M. Rothberg, Henri Lichenstein
  • Patent number: 11020486
    Abstract: Injectable formulations comprising ethanol, sesame oil, and an Immune Response Modifier compound are disclosed. Methods of making the formulations and methods of using the formulations for treatment of a disease in a subject, e.g., neoplastic disease, comprising injecting the formulations into a subject hi need of treatment, are also provided.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: June 1, 2021
    Assignee: 3M INNOVATIVE PROPERTIES COMPANY
    Inventors: Joseph M. Beaurline, James M. Elvecrog, John P. Vasilakos, John Thomas Capecchi, Karen Elizabeth Johnson
  • Patent number: 11021478
    Abstract: This invention relates to indolizine derivatives and their use in medicine. In particular, the present invention discloses novel substituted indolizine derivatives of formula I, or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer thereof, a tautomer thereof or a mixture of various isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof. The invention also relates to the use of these compounds in medicine.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: June 1, 2021
    Assignee: KIND PHARMACEUTICAL
    Inventors: Dong Liu, Dongdong Chen, Biao Deng, Xiangyun Tu, Zinan Fang, Haohao Wu, Danyan Gu
  • Patent number: 10844436
    Abstract: The present invention is directed to methods of prognosing, treating, or managing treatment of cancer in a subject. These methods involve selecting a subject having cancer, obtaining, from the selected subject, a sample containing exosomes, recovering the exosomes from the sample, and isolating the double-stranded DNA from within the exosomes. The isolated double-stranded DNA is then used to detect the presence or absence of one or more genetic mutations associated with cancer, quantify the amount of isolated double-stranded DNA from the recovered exosomes in the sample, detect the methylation status of the isolated double-stranded DNA, or quantify the amount isolated double-stranded DNA able to enter a recipient cell. The prognosing, treating, or managing treatment is carried out based on this information.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: November 24, 2020
    Assignees: CORNELL UNIVERSITY, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David C. Lyden, Hector Peinado Selgas, Haiying Zhang, Basant Kumar Thakur, Annette Becker, Jacqueline Bromberg
  • Patent number: 10835553
    Abstract: The invention discloses an application of hydroxypropyl methyl cellulose in preparation of medicines for treating esophageal mucosa. The invention discloses a hydroxypropyl methyl cellulose-containing composition which comprises the following ingredients: 1-28 weight parts of hydroxypropyl methyl cellulose and 1000 weight parts of purified water. A preparation method includes steps of adding the hydroxypropyl methyl cellulose, by stirring, into the purified water in an amount which accounts for 40% of the total amount of water used to obtain a mixed material, continuously stirring the mixed material until the mixed material is completely swelling and turning into a transparent solution, adding the remaining purified water to obtain a mixture, and stirring the mixture to obtain the hydroxypropyl methyl cellulose-containing composition.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: November 17, 2020
    Assignee: Hefei Jiuyan Pharmaceutical Science and Technology Development Co., Ltd.
    Inventors: Yu Gao, Yunli Bu
  • Patent number: 10813890
    Abstract: A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one NMDA-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, with component (a) being administered either before or after component (b), and with components (a) or (b) being administered to the mammal either via the same pathway of administration or via different pathways of administration.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: October 27, 2020
    Assignee: Grünenthal GmbH
    Inventors: Klaus Schiene, Petra Bloms-Funke
  • Patent number: 10711020
    Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: July 14, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingwu Duan, T. G. Murali Dhar, David Marcoux, Robert J. Cherney
  • Patent number: 10695327
    Abstract: A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, isomers, or N-oxides thereof.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: June 30, 2020
    Assignee: Elixir Medical Corporation
    Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
  • Patent number: 10688085
    Abstract: Provided are a pharmaceutical composition exhibiting therapeutic efficacy against EML4-ALK-positive non-small cell lung cancer that has acquired resistance to an ALK inhibitor and a method for treating the non-small cell lung cancer. Further, provided is information for drug selection for determining whether to administer a statin-based drug to a patient group with EML4-ALK-positive non-small cell lung cancer.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: June 23, 2020
    Assignees: UNIVERSITY-INDUSTRY FOUNDATION, YONSEI UNIVERSITY, JEUK CO., LTD.
    Inventors: Kyoung-Je Cho, Byoung Chul Cho, Mi-Ran Yun, Kyoung-Ho Pyo, Han Na Kang, Hun-Mi Choi
  • Patent number: 10634668
    Abstract: Methods of reversibly inducing proximity of first and second target molecules in a sample are provided. Aspects of the methods include contacting the sample with a modifiable chemical inducer of proximity (MCIP) that reversibly induces proximity of the first and second target molecules, upon application of a stimulus that modifies the MCIP. Aspects of the invention further include methods for regulating a biological process in a cell. Aspects of the invention further include compositions, e.g., compounds and kits, etc., that find use in methods of the invention.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: April 28, 2020
    Assignee: TAKARA BIO USA, INC.
    Inventors: Eric Espinosa, Andrew Farmer
  • Patent number: 10632108
    Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: April 28, 2020
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Ulhas R. Dhuppad, Franciscus Koppenhagen, Sunil Chaudhari, Suresh Rajurkar, Chandrakant Dhatrak, Alkesh Kasliwal
  • Patent number: 10624884
    Abstract: The present invention concerns the use of an H4 agonist molecule against histamin, enantiomers of (AMINO-7 TRIETHOXY-4,5,6 OXO-1 DIHYDRO-1,3 ISOBENZOFURANNYL-3)-1 METHOXY-8 METHYL-2 METHYLENEDIOXY-6,7 TETRAHYDRO-,2,3,4 ISOQUINOLINE or tritoqualine, for the treatment of idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: April 21, 2020
    Assignee: H4 ORPHAN PHARMA
    Inventors: Gaëtan Terrasse, Catherine Bur
  • Patent number: 10617678
    Abstract: Described herein are methods for distributing temsirolimus to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of temsirolimus for delivery into the tissue surrounding a blood vessel for treating vascular diseases.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: April 14, 2020
    Assignee: MERCATOR MEDSYSTEMS, INC.
    Inventor: Kirk Patrick Seward
  • Patent number: 10596107
    Abstract: A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90<5 ?m and Dv50<1 ?m. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: March 24, 2020
    Assignee: Bausch & Lomb Incorporated
    Inventors: Mohannad Shawer, Eric Phillips, Martin J. Coffey
  • Patent number: 10576063
    Abstract: Described herein are methods for distributing a combination of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone for delivery into the tissue surrounding a blood vessel for treating vascular diseases.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: March 3, 2020
    Assignee: Mercator MedSystems, Inc.
    Inventor: Kirk Patrick Seward
  • Patent number: 10548861
    Abstract: Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: February 4, 2020
    Assignees: Academia Sinica, Memorial Sloan Kettering Cancer Center
    Inventors: Malcolm Moore, Jae-Hung Shieh, Tsann-Long Su, Te-Chang Lee
  • Patent number: 10492356
    Abstract: The invention encompasses a nontoxic agricultural formulation of a concentrated liquid suspension comprising an organic phase and suspended particulate materials, and also encompasses an aqueous formulation comprising the concentrated liquid suspension and an agricultural treatment agent. The invention additionally encompasses methods of treating an agricultural target, comprising providing an agricultural formulation of a concentrated liquid suspension comprising an organic phase and suspended particulates, and applying the agricultural formulation onto the agricultural target, thereby treating the agricultural target.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: December 3, 2019
    Assignee: CROP ENHANCEMENT, INC.
    Inventors: Jonathan Flores, Matthew A. Bosley, Sandra Rifai, Robert P. Mahoney, Damian Hajduk, Rosa Casado Portilla, Turner Newton, David S. Soane
  • Patent number: 10456383
    Abstract: Methods are provided for the targeted treatment of Epidermolysis Bullosa simplex.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: October 29, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Joyce Teng, Heather Irina Rishel, Dédée F. Murrell
  • Patent number: 10358448
    Abstract: The invention provides compounds of Formula 1: and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: July 23, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bart DeCorte, Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee
  • Patent number: 10307452
    Abstract: A method of reducing the number of microorganisms entering the nose and proliferating in the nasal cavity including application of a solution of an antimicrobial, antiviral and antifungal composition to the anterior vestibular region of the nares. The antimicrobial, antiviral and antifungal solution includes ethyl alcohol as an active ingredient. Various embodiments may also include one or more of the following additional ingredients: orange oil; lemon oil; grapefruit oil; tangerine oil; mandarin oil; lime oil; bergamot oil; petitgrain essential oil; and other citrus oils; meadowfoam seed oil; soy oil; emu oil; grapefruit seed extract; glycine soja; simmondsia chinensis (Jojoba); lauric acid; chlorhexidine gluconate; ginger oil; lavender oil; peppermint oil; spearmint oil; aloe oil; one or more terpenes and/or terpenoids; and a preservative, such as benzalkonium chloride and vitamin E.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: June 4, 2019
    Assignee: GLOBAL LIFE TECHNOLOGIES CORP.
    Inventor: John A. Willimann
  • Patent number: 10258565
    Abstract: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in the blood vessel and are useful for treating various diseases.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: April 16, 2019
    Assignees: ABRAXIS BIOSCIENCE, LLC, MERCATOR MEDSYSTEMS, INC.
    Inventors: Kirk Seward, Neil P. Desai
  • Patent number: 10207988
    Abstract: The technology described herein relates to methods of inducing cell death. The technology described herein further relates to treating conditions including cancers and autoimmune diseases comprising administering inhibitors of double strand break repair. Also described herein are inhibitors of double strand break repair and methods of screening for such inhibitors.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 19, 2019
    Assignee: THE JACKSON LABORATORY
    Inventors: Kevin David Mills, Muneer Gulamhusien Hasham, Caroline Gardner McPhee
  • Patent number: 10201533
    Abstract: The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R1, R2, R3, R4, R5, R9 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: February 12, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tao Yu, Yonglian Zhang, Sherman Tim Waddell, John M. Sanders, Thomas H. Graham, Hong Li
  • Patent number: 10166190
    Abstract: The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: January 1, 2019
    Assignee: VELOXIS PHARMACEUTICALS A/S
    Inventors: Nikolaj Skak, Per Holm
  • Patent number: 10143682
    Abstract: A medicine for improving the state of pregnancy, which comprises a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient; and a use of the medicine.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: December 4, 2018
    Assignee: KOUSHI YAMAGUCHI
    Inventor: Koushi Yamaguchi
  • Patent number: 10123996
    Abstract: A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, isomers, or N-oxides thereof.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: November 13, 2018
    Assignee: Elixir Medical Corporation
    Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
  • Patent number: 10039839
    Abstract: The invention relates to macrocyclic compounds capable of modulating biological processes through binding to a presenter protein and a target protein. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity. In some embodiment, the compounds of the invention “re-program” the binding of the presenter proteins to protein targets that either do not normally bind to the presenter protein.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: August 7, 2018
    Assignee: Warp Drive Bio, Inc.
    Inventors: Gregory Lawrence Verdine, Matthew James Nichols, Dylan Talbot Stiles, Neville John Anthony, Brian Roger Bowman, Mathew Edward Sowa, Sharon Ann Townson
  • Patent number: 9987260
    Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: June 5, 2018
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Ulhas Dhuppad, Franciscus Koppenhagen, Sunil Chaudhari, Suresh Rajurkar, Chandrakant Dhatrak, Alkesh Kasliwal
  • Patent number: 9974796
    Abstract: Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: May 22, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Sanjay A. Desai, Ajay D. Pillai
  • Patent number: 9957266
    Abstract: The present invention relates to compounds that may be used for binding and imaging tau aggregates and related beta-sheet aggregates including, for example, beta-amyloid aggregates or alpha-synuclein aggregates.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: May 1, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Luca Gobbi, Henner Knust, Matthias Koerner, Dieter Muri
  • Patent number: 9920377
    Abstract: The disclosure provides methods for predicting and/or determining whether a subject has cancer based on the level of expression of BPTF. The disclosure also provides methods for determining whether a cancer in a subject is progressing or regressing based upon the change of expression levels of BPTF between two time points. The disclosure further provides methods to treat a subject with a cancer by administering a polynucleotide comprising an inhibitory BPTF nucleic acid and/or an agent that inhibits the expression or activity of BPTF.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: March 20, 2018
    Assignee: SUTTER WEST BAY HOSPITALS
    Inventors: Mohammed Kashani-Sabet, Altaf A. Dar
  • Patent number: 9918968
    Abstract: The invention provides for treatment of cancers using a rapamycin analog, optionally including bortezomib. In particular, the invention addresses the treatment of bortezomib-resistant cancers using seco-rapamycin and optionally a second proteasome inhibitor. This invention relates to oncology and medicine, and more particularly to treatment of cancer. In particular, rapamycin analogs such as seco-rapamycin may be used advantageously to target the proteasome in cancer cells, optionally in conjunction with proteasome inhibitors such as bortezomib.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: March 20, 2018
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maria E. Gaczynska, Pawel A. Osmulski
  • Patent number: 9884013
    Abstract: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in the blood vessel and are useful for treating various diseases.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: February 6, 2018
    Assignees: Abraxis BioScience, LLC, Mercator MedSystems, Inc.
    Inventors: Kirk Seward, Neil P. Desai
  • Patent number: 9855253
    Abstract: The present invention relates to a pharmaceutical composition containing FK506 derivative for treating a fungal infection caused by the genus Cryptococcus or the genus Candida, and a use thereof. In addition, the present invention relates to a therapeutic agent for fungal infection caused by the genus Cryptococcus or the genus Candida, the therapeutic agent containing FK506 derivative. The pharmaceutical composition of the present invention is harmless to the human body, and can make a great contribution to providing antifungal drugs with an excellent antifungal effect.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: January 2, 2018
    Assignee: INTRON BIOTECHNOLOGY CO., LTD.
    Inventors: Yong Sun Bahn, Hyo Jeong Kwon, Yeo Joon Yoon, Yeon Hee Ban
  • Patent number: 9855252
    Abstract: A method of treating or preventing keratin hyperproliferation skin disorders is set forth. The method includes the administration of an mTOR inhibitor to a subject afflicted with the hyperproliferation disorder. The mTOR inhibitor can be administered to the subject via any means known in the art including oral, topical, and transdermal administration.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: January 2, 2018
    Assignee: PALVELLA THERAPEUTICS, LLC
    Inventors: Roger Louis Kaspar, Robyn Patricia Hickerson
  • Patent number: 9844597
    Abstract: The present invention provides compositions, and related kits and methods, for formation of hydrogels. The compositions comprise one or more chemically crosslinkable agents dissolved in an aqueous solution to form a precursor solution. The chemically crosslinkable agents useful in the present invention are selected from polymers modified with a molecule selected from acrylate, maleimide, vinylsulfone, N-hydroxysuccinimide, aldehyde, ketone, carbodiimide, carbonate, iodoacetyl, mercaptonicotinamide, quinone, thiol, amine, and combinations thereof. The precursor solution is characterized as being in an aqueous form at a non-physiologic physical-chemical condition and undergoing gelation when in contact with another fluid or body at a physiologic physical-chemical condition.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: December 19, 2017
    Assignee: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Ying Chau, Yu Yu, Jieying Zhong
  • Patent number: 9840515
    Abstract: Compounds according to Formula (I), are potent inhibitors of protein kinase D (pan-PKD) activity. PKD controls key signaling cascades in cells, affecting cell proliferation, gene transcription, and protein trafficking. Accordingly, pharmaceutically acceptable compositions of the inventive compounds are candidate therapeutics for pathological conditions conditioned by changes in PKD activity.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: December 12, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Qiming Jane Wang
  • Patent number: 9815859
    Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: November 14, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingwu Duan, T. G. Murali Dhar, David Marcoux, Qing Shi, Douglas G. Batt, Qingjie Liu, Robert J. Cherney, Lyndon A. M. Cornelius, Anurag S. Srivastava, Myra Beaudoin Bertrand, Carolyn A. Weigelt
  • Patent number: 9789141
    Abstract: This invention relates to use of probiotics, particularly P acidilactici and S boulardii, for use in conjunction with steroids and other immune suppressor agents to ameliorate symptoms of autoimmune diseases, especially disease symptoms arising from the body's production of antibodies against autologous blood cells. The practice of the invention sustains ameliorative response associated with immune suppressor agents while lowering the amount of immune suppressor agents required for treatment.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: October 17, 2017
    Assignee: IMAGILIN TECHNOLOGY, LLC
    Inventors: Jhy-Jhu Lin, Gen Kato, Takuo Ishida
  • Patent number: 9765082
    Abstract: A cocrystal of tiotropium bromide and lactose monohydrate is herein disclosed. In the cocrystal the components tiotropium bromide and lactose are preferably present in an almost stoichiometric ratio. Said cocrystal has a single endothermic event at about 191-193° C. determined by DSC. A process for the preparation of the cocrystal is also disclosed. Preferably, the cocrystal has a particle size distribution of D90<10 ?m. The cocrystal is also disclosed for use as medicament, in particular for the treatment of a respiratory complaint, such as chronic obstructive pulmonary disease (COPD), bronchitis, emphysema and asthma. A pharmaceutical composition comprising the cocrystal as active ingredient is also disclosed, in particular for administration by inhalation. In the latter case, said cocrystal has a mean particle size of 0.5 to 10 ?m, preferably 1 to 6 ?m, more preferably 1.5 to 5 ?m.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: September 19, 2017
    Assignee: EUTICALS SPA
    Inventors: Paride Grisenti, Maria Argese, Roberto Scrocchi, Alessandro Livieri, Giuseppe Guazzi
  • Patent number: 9757365
    Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: September 12, 2017
    Assignee: Glenmark Specialty S.A.
    Inventors: Ulhas Dhuppad, Franciscus Koppenhagen, Sunil Chaudhari, Suresh Rajurkar, Chandrakant Dhatrak, Alkesh Kasliwal
  • Patent number: 9730918
    Abstract: The present disclosure provides methods of using protein kinase inhibitors for treating diseases and conditions, including diseases and conditions associated with activity of any protein kinase selected from Fms protein kinase including any mutations thereof, Kit protein kinase any mutations thereof, Flt-3 protein kinase any mutations thereof and combinations thereof.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: August 15, 2017
    Assignee: Plexxikon Inc.
    Inventors: Gideon Bollag, Klaus-Peter Hirth, Prabha N. Ibrahim, Paul Lin, Brian West
  • Patent number: 9717721
    Abstract: Aryl-quinolin derivatives for use in inhibiting vasculogenic mimicry, treating diseases characterized by abnormal vascular morphology or function and/or by the presence of vasculogenic mimicry in a subject in need thereof are disclosed. In one embodiment of the invention, the compounds are for use in treating metastatic tumor, hyperproliferative, or angiogenic diseases. In another embodiment of the invention, the compound for use may combine an additional therapeutic agent such as anti-cancer agents, anti-inflammatory agents, anti-proliferative agents, anti-hormonal agents, or any combination thereof for use.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: August 1, 2017
    Assignee: TAIRX, INC.
    Inventors: Yi-Wen Chu, Du-Shieng Chien
  • Patent number: 9687523
    Abstract: This invention provides a method of inducing a lacrimal acinar cell in a tissue to degrade a secretory vesicle and its content protein or proteins from the trans-Golgi network (TGN) by contacting the cells with an effective amount of an agent that induces autophagy. Also provided is a method for treating a mammal suffering from defective trans-Golgi network-secretory vesicle (TGN-SV) sorting by administering to the mammal an effective amount of an agent that induces autophagy in the tissue having the defective TGN-SV.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: June 27, 2017
    Assignee: University of Southern California
    Inventor: Sarah Hamm-Alvarez